155 related articles for article (PubMed ID: 30233672)
1. SPARCL1 suppresses the proliferation and migration of human ovarian cancer cells via the MEK/ERK signaling.
Ma Y; Xu Y; Li L
Exp Ther Med; 2018 Oct; 16(4):3195-3201. PubMed ID: 30233672
[TBL] [Abstract][Full Text] [Related]
2. SPARCL1 suppresses cell migration and invasion in renal cell carcinoma.
Ye H; Wang WG; Cao J; Hu XC
Mol Med Rep; 2017 Nov; 16(5):7784-7790. PubMed ID: 28944877
[TBL] [Abstract][Full Text] [Related]
3. The inhibition of HeLa cells proliferation through SPARCL1 mediated by SPP1.
Zhang S; Zhang F; Feng L
Cytotechnology; 2021 Feb; 73(1):71-78. PubMed ID: 33505115
[TBL] [Abstract][Full Text] [Related]
4. SPARCL1 suppresses metastasis in prostate cancer.
Xiang Y; Qiu Q; Jiang M; Jin R; Lehmann BD; Strand DW; Jovanovic B; DeGraff DJ; Zheng Y; Yousif DA; Simmons CQ; Case TC; Yi J; Cates JM; Virostko J; He X; Jin X; Hayward SW; Matusik RJ; George AL; Yi Y
Mol Oncol; 2013 Dec; 7(6):1019-30. PubMed ID: 23916135
[TBL] [Abstract][Full Text] [Related]
5. MiR-539-3p promotes the progression of epithelial ovarian cancer by targeting SPARCL1.
Gong YB; Fan XH
Eur Rev Med Pharmacol Sci; 2019 Mar; 23(6):2366-2373. PubMed ID: 30964161
[TBL] [Abstract][Full Text] [Related]
6. Secreted protein acidic and rich in cysteines-like 1 suppresses aggressiveness and predicts better survival in colorectal cancers.
Hu H; Zhang H; Ge W; Liu X; Loera S; Chu P; Chen H; Peng J; Zhou L; Yu S; Yuan Y; Zhang S; Lai L; Yen Y; Zheng S
Clin Cancer Res; 2012 Oct; 18(19):5438-48. PubMed ID: 22891198
[TBL] [Abstract][Full Text] [Related]
7. Androgen-Regulated SPARCL1 in the Tumor Microenvironment Inhibits Metastatic Progression.
Hurley PJ; Hughes RM; Simons BW; Huang J; Miller RM; Shinder B; Haffner MC; Esopi D; Kimura Y; Jabbari J; Ross AE; Erho N; Vergara IA; Faraj SF; Davicioni E; Netto GJ; Yegnasubramanian S; An SS; Schaeffer EM
Cancer Res; 2015 Oct; 75(20):4322-34. PubMed ID: 26294211
[TBL] [Abstract][Full Text] [Related]
8. Secreted protein acidic and rich in cysteine-like 1 suppresses metastasis in gastric stromal tumors.
Shen C; Yin Y; Chen H; Wang R; Yin X; Cai Z; Zhang B; Chen Z; Zhou Z
BMC Gastroenterol; 2018 Jul; 18(1):105. PubMed ID: 29973149
[TBL] [Abstract][Full Text] [Related]
9. Associations of tumor suppressor SPARCL1 with cancer progression and prognosis.
Li T; Liu X; Yang A; Fu W; Yin F; Zeng X
Oncol Lett; 2017 Sep; 14(3):2603-2610. PubMed ID: 28927026
[TBL] [Abstract][Full Text] [Related]
10. SPARCL1 Influences Bovine Skeletal Muscle-Derived Satellite Cell Migration and Differentiation through an ITGB1-Mediated Signaling Pathway.
Wang Y; Liu S; Yan Y; Li S; Tong H
Animals (Basel); 2020 Aug; 10(8):. PubMed ID: 32781616
[TBL] [Abstract][Full Text] [Related]
11. MicroRNA-508 suppresses epithelial-mesenchymal transition, migration, and invasion of ovarian cancer cells through the MAPK1/ERK signaling pathway.
Hong L; Wang Y; Chen W; Yang S
J Cell Biochem; 2018 Sep; 119(9):7431-7440. PubMed ID: 29781537
[TBL] [Abstract][Full Text] [Related]
12. The tumour suppressor DiRas3 interacts with C-RAF and downregulates MEK activity to restrict cell migration.
Klingauf M; Beck M; Berge U; Turgay Y; Heinzer S; Horvath P; Kroschewski R
Biol Cell; 2013 Feb; 105(2):91-107. PubMed ID: 23157514
[TBL] [Abstract][Full Text] [Related]
13. [Expression and significance of MAPK/ERK in the specimens and cells of epithelial ovarian cancer].
Jiang XL; Gao JC; Jiang L; Zhang PX; Kang TJ; Sun Q; Qi WJ; Zhang QP; Guan HW; Shi H
Zhonghua Fu Chan Ke Za Zhi; 2019 Aug; 54(8):541-547. PubMed ID: 31461811
[No Abstract] [Full Text] [Related]
14. SPARCL1 is a novel predictor of tumor recurrence and survival in hilar cholangiocarcinoma.
Yu Y; Chen Y; Ma J; Yu X; Yu G; Li Z
Tumour Biol; 2016 Mar; 37(3):4159-67. PubMed ID: 26490986
[TBL] [Abstract][Full Text] [Related]
15. Prognostic value of SPARCL1 in patients with colorectal cancer.
Han W; Cao F; Ding W; Gao XJ; Chen F; Hu YW; Ding HZ
Oncol Lett; 2018 Feb; 15(2):1429-1434. PubMed ID: 29434834
[TBL] [Abstract][Full Text] [Related]
16. [Relationship between raf kinase inhibitor protein and metastasis of ovarian carcinoma].
Wang Y; Yang J; Gao Y; Zhao XL; Li HZ; Yao Z
Zhonghua Fu Chan Ke Za Zhi; 2009 Jul; 44(7):522-8. PubMed ID: 19957553
[TBL] [Abstract][Full Text] [Related]
17. ALDH1A2 suppresses epithelial ovarian cancer cell proliferation and migration by downregulating STAT3.
Wang Y; Shao F; Chen L
Onco Targets Ther; 2018; 11():599-608. PubMed ID: 29430185
[TBL] [Abstract][Full Text] [Related]
18. Expression of SPARC like protein 1 (SPARCL1), extracellular matrix-associated protein is down regulated in gastric adenocarcinoma.
Jakharia A; Borkakoty B; Singh S
J Gastrointest Oncol; 2016 Apr; 7(2):278-83. PubMed ID: 27034797
[TBL] [Abstract][Full Text] [Related]
19. MEK1/2 inhibitors in the treatment of gynecologic malignancies.
Miller CR; Oliver KE; Farley JH
Gynecol Oncol; 2014 Apr; 133(1):128-37. PubMed ID: 24434059
[TBL] [Abstract][Full Text] [Related]
20. PD98059 impairs the cisplatin-resistance of ovarian cancer cells by suppressing ERK pathway and epithelial mesenchymal transition process.
Hou L; Hou X; Wang L; Li Z; Xin B; Chen J; Gao X; Mu H
Cancer Biomark; 2017 Dec; 21(1):187-194. PubMed ID: 29103028
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
